Dan Skovronsky, Eli Lilly CSO (Purdue University)
February 10, 2021 06:27 AM EST
FDA+
Coronavirus

Eli Lil­ly racks up EUA for an­ti­body cock­tail — but the big­ger chal­lenge is still ahead

Amber Tong

Eli Lil­ly has be­come the first drug­mak­er to have three Covid-19 treat­ments au­tho­rized for emer­gency use by the FDA, rack­ing up …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times